Drug intelligence / Profile preview

VYR-109

Development stage: Preclinical
Lead developer: Vyripharm International
Modality: Hydrogel Systems → Drug Delivery Systems

Overview

VYR-109 is a hydrogel-based drug delivery system under development by Vyripharm International for the treatment of cancer. The system is designed to provide controlled or localized release of therapeutic agents to improve treatment outcomes and potentially reduce systemic side effects. As of 2021, the program was in the IND-enabling stage of development. While Vyripharm's broader portfolio includes medical cannabinoids and radiopharmaceuticals, the specific therapeutic agent utilized in the VYR-109 formulation has not been publicly disclosed.

Beyond the preview

Go deeper on VYR-109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-109.

Explore the full profile